deltatrials
Completed PHASE1/PHASE2 NCT01348100

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days

Sponsor: Novartis Pharmaceuticals

Conditions Schizophrenia
Interventions Iloperidone crystalline formulation Iloperidone microparticle formulation Oral iloperidone
Updated 6 times since 2017 Last updated: Dec 17, 2013 Started: Apr 30, 2011 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

Listed as NCT01348100, this PHASE1/PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2011, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
  • Vanda Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Glendale, United States
  • • Philadelphia, United States